EUCTR2009-018119-14-GB进行中（未招募）1 期
Huntington's Disease Rilmenidine Safety Trial - Huntington's Disease Rilmenidine study
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge0 个研究点目标入组 16 人开始时间: 2010年6月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Confirmed diagnosis of Huntington’s Disease on the basis of qualifying clinical signs and symptoms as well as a relevant family history, or a CAG repeat of >36 on exon 1 of the htt gene.
- •2. HD stage 1-3 with a total functioning capacity (TFC) on the Unified Huntington’s Disease Rating Scale 1999 (UHDRS) of at least 5.
- •3. Able to self care independently and are ambulant.
- •4. Aged from 18 and 70.
- •5. Women of childbearing age neither pregnant nor planning to conceive during the period of the study.
- •6. English speaking and able to provide written, informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1.An ongoing clinically significant and unstable General Medical Condition (including but not limited to; asthma, chronic obstructive pulmonary disease COPD, unstable ischaemic heart disease IHD, congestive cardiac failure CCF, left bundle branch block LBBB or a cerebral vascular accident CVA) confirmed via past medical history or baseline medical physical examination and investigations.
- •2.Prescribed anti-hypertensive medication or any drug known to be contraindicated or to have an adverse interaction with Rilmenidine (viz. a Monoamine Oxidase Inhibitor).
- •3.Known hypersensitivity to Rilmenidine.
- •4.Ongoing significant mental illness determined by evidence or a history of a psychotic or affective (depression or mania) episode in the six months prior to Baseline Interview assessed using the Diagnostic and Statistical Manual of Mental Disorders criteria (Fourth Edition with Text Revision; American Psychiatric Association).
- •5.Prescribed typical or atypical anti-psychotic medication (only if being prescribed explicitly for treatment of a psychotic illness).
- •6.Pregnant or breastfeeding female patients, including those planning to conceive during the period of the trial.
- •7.Substance (alcohol or illegal/prescription drug) misuse in the six months prior to the baseline assessment.
- •8.Known co-morbid major neurological disorder (incl. Parkinson’s Disease or dementia), HIV/AIDS or Hepatitis (HBV or HCV).
- •9.Previous neurosurgery to the brain.
- •10.Marked clinically adverse abnormalities on laboratory investigations including creatinine clearance <15mg/min or creatinine serum level >177 Umol/l.
研究者
相似试验
已完成
1 期
A phase I clinical trial to investigate the safety, tolerability and efficacy of two candidate Mycobacterium avium subspecies paratuberculosis (MAP) vaccines in patients with active Crohn's diseaseDigestive SystemCrohn's diseaseISRCTN36126048HAV Vaccines Limited28
已完成
1 期
First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NOX-H94MedDRA - LLT 10002272 (Anämie / Anemia)D63Anaemia in chronic diseases classified elsewhereDRKS00003102OXXON Pharma AG64
已完成
2 期
Clinical study to investigate safety, tolerability, efficacy,pharmacokinetics and pharmacodynamics of inhaled multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with moderate to severe COPD– A randomised, double-blind, parallel group, multicenter, phase IIa pilot study –J44.9Chronic obstructive pulmonary disease, unspecifiedDRKS00006087Philipps-Universität Marburg19
进行中（未招募）
不适用
Clinical study to investigate safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with mild allergic asthmaEUCTR2012-003570-77-DEsterna biologicals GmbH & Co. KG
已完成
不适用
A First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Oral Doses of JNJ 28431754 in Healthy Male SubjectsDiabetes Mellittus type II10018424NL-OMON30637Janssen-Cilag56